Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

MLA

A. Hans Vija, et al. “Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.” Journal of Nuclear Medicine, vol. 61, Sept. 2019, pp. 520–26. EBSCOhost, https://doi.org/10.2967/jnumed.119.233031.

APA

A. Hans Vija, Tilman T. Rau, Michal Cachovan, Emanuel Christ, Anne Schumann, Felix Kaul, Christof Rottenburger, Martin Béhé, Susanne Geistlich, Damian Wild, Guillaume Nicolas, Katharina Glatz, Lisa McDougall, & Roger Schibli. (2019). Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. Journal of Nuclear Medicine, 61, 520–526. https://doi.org/10.2967/jnumed.119.233031

Chicago

A. Hans Vija, Tilman T. Rau, Michal Cachovan, Emanuel Christ, Anne Schumann, Felix Kaul, Christof Rottenburger, et al. 2019. “Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.” Journal of Nuclear Medicine 61 (September): 520–26. doi:10.2967/jnumed.119.233031.